Both Moderna and AstraZeneca have used cutting-edge designs to reduce their vaccines' development time.
A group of 28 vaccine researchers said we might have a vaccine by late-2021, though it could take until well into 2022.
With $1 billion in advance purchase agreements for COVID-19 vaccines, Canada has joined the vaccine nationalists: rich countries buying up more than half the global short-term supply of vaccine.
Will a vaccine for COVID-19 be safe? Animal testing, human clinical trials and post-approval surveillance give us good grounds to believe that a future approved vaccine will work and be safe.
Our best shot at ending the pandemic is by achieving herd immunity through widespread use of a vaccine. But that won’t happen unless people believe it’s safe.
The COVID-19 vaccine is in the final stages of testing – meaning we should know whether it’s effective before the end of the year.
Church leaders have raised concerns over a COVID-19 vaccine produced using cells derived from aborted foetuses. But the Vatican has already ruled such vaccines ‘morally separate’ from the abortions.
The vaccine hasn’t completed phase 3 trials, so we can’t be sure it will be safe and effective for all. The Australian government’s deal is contingent on these trials being successful.
A two-dose coronavirus vaccine would mean we need to produce 12-15 billion doses. This is roughly twice the world’s current total vaccine manufacturing capacity.
If the vaccine does not protect individuals from infection, those who have been vaccinated could falsely believe they are protected.
The race is on to develop a vaccine for the COVID-19 coronavirus. Australian researchers are leading several major clinical trials that might help bring an end to the deadly disease.
Immunosenescence — the decline of immune system function with age — means that vaccines are not as effective in older adults, the demographic most susceptible to many diseases, including COVID-19.
The experimental vaccine stimulates the creation of antibodies. Now we need to show that these effectively protect us from the coronavirus.
There isn’t enough clinical research being done in Africa. This has had a lot of repercussions in terms of the timing when interventions become available and effective in high income countries.
Word that the U.S. has bought up the entire supply of the COVID-19 drug remdesivir is another reminder that in a pandemic, treatments and vaccines need to be accessible to everyone, globally.
It usually takes 10 years for a new vaccine to complete clinical trials, but we’ve been promised a COVID-19 vaccine in 12 to 18 months. Even if such fast-tracked development is possible, is it wise?
Politicians are throwing billions of dollars at coronavirus vaccine trials, but the real cost of research is the one thing we’re lacking – time.
As most of the world early awaits a vaccine for COVID-19, a smaller group of people scoffs. They could spell real trouble in the effort to build widespread immunity.
A test that detects antibodies against the coronavirus behind COVID-19 would reveal those people who have already encountered the virus - and therefore who might be ok to resume normal life.
Researchers around the world are working hard on developing a vaccine – but the process may still take 12-18 months. Here’s why.